Economics of non-adherence to biologic therapies in rheumatoid arthritis

TitleEconomics of non-adherence to biologic therapies in rheumatoid arthritis
Publication TypeJournal Article
Year of Publication2014
AuthorsDe Vera MA, Mailman J, Galo JS
JournalCurr Rheumatol Rep
Date Published11/2014

Adherence to biologic therapies among patients with rheumatoid arthritis is sub-optimal, with the proportion of adherent patients reported to be as low as 11 %. We found few studies evaluating economic outcomes, including health care costs, associated with non-adherence with biologic therapies. Findings suggest that while higher pharmacy costs drive total health care costs among adherent patients, non-adherent patients incur greater health care utilization including inpatient, outpatient, and laboratory services. Finally, economic factors are important determinants of adherence to biologics in patients with rheumatoid arthritis. Evidence to date has shown that higher out-of-pocket payments have a negative association with adherence to biologics. Furthermore, cost-related non-adherence is a highly prevalent problem in rheumatoid arthritis. Given the high costs of biologics and continued expansion of use in rheumatoid arthritis, there is need for more research to understand the economic implications of adherence to these therapies.

Alternate JournalCurr Rheumatol Rep
PubMed ID25227187